Objective: To investigate the safety of neoadjuvant chemotherapy and conization in early-stage cervical cancer with a tumor size >2 cm using a fertility-sparing approach.
Methods: The ETERNITY project is a retrospective, multi-institutional study that collected data from patients with early-stage cervical cancer undergoing fertility-sparing treatment. In the present study, we report the outcomes of stage IB2 to IB3 cervical cancer undergoing nodal assessment, neoadjuvant chemotherapy, and conization. A propensity-matching algorithm was used to compare patients who underwent upfront radical surgery.
Results: A total of 395 patients were included in the ETERNITY project. Among these, 25 underwent a fertility-sparing attempt with nodal assessment, neoadjuvant chemotherapy, and conization. The median (range) patient age was 37 (24-41) years. Four (16%) patients with positive nodes required definitive chemo-radiation. Twenty-one (84%) patients received neoadjuvant chemotherapy. Two (8%) patients with stable disease underwent radical hysterectomy, whereas the remaining 19 (76%) patients who achieved a clinical response underwent cervical conization. Three (12%) patients underwent radical hysterectomy owing to persistent positive margins, leaving 16 (64%) patients who completed the planned fertility-sparing attempt. After a median (range) follow-up of 36.2 (21.9-88) months, 3 recurrences occurred. Two patients with cervical recurrence underwent hysterectomy, while 1 patient who received definitive chemoradiotherapy owing to the presence of positive nodes developed distant recurrence. Regarding obstetric outcomes, 6 patients attempted to conceive, and 4 (66.7%) pregnancies were achieved (1 was achieved with assisted reproductive technology). In a propensity-matched group of patients who underwent upfront radical surgery, no differences in morbidity or survival rates were recorded.
Conclusions: Neoadjuvant chemotherapy followed by conization should be investigated in selected patients with cervical cancer who wish to preserve their childbearing potential. Further prospective studies are needed to assess the long-term safety and identify predictors of response.
Clinical Trial Identifier: NCT06351228.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijgc.2025.101643 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, synthesis and biological evaluation of pyrazolo[3,4-]pyridine derivatives as dual CDK2/PIM1 inhibitors with potent anti-cancer activity and selectivity.
J Biomol Struct Dyn
March 2025
Applied Organic Chemistry Department, National Research Center, Dokki, Egypt.
The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-]pyridine derivatives (), confirmed spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay.
View Article and Find Full Text PDFMapping the landscape of vitamin D in cancer studies: a systematic global investigation.
J Diabetes Metab Disord
June 2025
Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: This comprehensive study examines the multifaceted relationship between vitamin D and cancer, synthesizing key scientific advancements and global research trends to guide future investigations and address critical gaps in the field.
Methods: Publications on vitamin D and cancer were retrieved from Scopus up to November 2024. English-language original and review articles were analyzed using Excel, VOSviewer, and Scimago Graphica, focusing on publication trends, citation impacts, and research themes.
Enhancing Cancer Screening and Early Diagnosis in India: Overcoming Challenges and Leveraging Emerging Technologies.
Cureus
February 2025
Anatomy, All India Institute of Medical Sciences, Madurai, Madurai, IND.
This review addresses the significant challenges and technological developments in cancer screening and early diagnosis in the context of India's diverse and resource-constrained healthcare landscape. Selected cancers like breast, cervical, oral, lung, and colorectal cancers are focused on, and established screening methods such as clinical breast examination (CBE), mammography, visual inspection with acetic acid (VIA), HPV DNA testing, and oral visual inspection (OVI) are reviewed. These are cost-effective strategies that are proven to reduce mortality.
View Article and Find Full Text PDFIdentification of Thyroid Genes Whose Expression Is Altered by Neonatal Irradiation in Rats.
Int J Mol Sci
February 2025
Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.
Childhood radiation is a risk factor for thyroid cancer that became well known after the Chernobyl nuclear plant accident. Although these human cases have been extensively studied, the mechanisms underlying childhood susceptibility to radiation-induced thyroid cancer have yet to be explained. Our previous study showed that neonatal X-irradiation resulted in long-term alterations in the mRNA expression of thyroid cancer-related marker genes, which may be a critical mechanism for understanding the higher radiation sensitivity in young patients.
View Article and Find Full Text PDFDevelopment and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.
Int J Mol Sci
February 2025
School of Life Sciences Pharmacy and Chemistry, Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK.
Primary or acquired resistance to therapeutic agents is a major obstacle in the treatment of cancer patients. Cervical cancer is the fourth leading cause of cancer deaths among women worldwide and, despite major advances in cancer screening and treatments, many patients with advanced stage cervical cancer have a high recurrence rate within two years of standard treatment, with drug resistance being a major contributing factor. The development of cancer cell lines with acquired resistance to therapeutic agents can facilitate the comprehensive investigation of resistance mechanisms, which cannot be easily performed in clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!